TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025

Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.

Elizabeth M Burton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.